metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)
versus trastuzumab
	trastuzumab emtansine vs. trastuzumab	1	0.70 [0.47; 1.05], 1 RCT, I2=0% inconclusive result	-	-
versus trastuzumab plus endocrine therapy
	trastuzumab emtansine vs. trastuzumab plus endocrine therapy	1	-	-	-
	trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy	1	-	-	-
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	trastuzumab emtansine vs. lapatinib plus capecitabine	1	0.68 [0.55; 0.85], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.65 [0.55; 0.77], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus trastuzumab emtansine
	trastuzumab deruxtecan vs. trastuzumab emtansine	1	0.55 [0.36; 0.85], 1 RCT, I2=0% unassessable degree of certainty	0.28 [0.22; 0.36], 1 RCT, I2=0% unassessable degree of certainty	-